Clinical Insights Into Anti‐Sulfatide Antibodies in Peripheral Neuropathies: A Retrospective Study
Authors:
- Ruo-Nan DuanRDRuo-Nan Duan
- Wei-Yue SiWSWei-Yue Si
- Ying LiuYLYing Liu
- Yi-Ming LiuYLYi-Ming Liu
- Rui-Sheng DuanRDRui-Sheng Duan
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Abstract
Background: Sulfatide, synthesized from glycosphingolipids via sulfation of the hydroxyl group, is a prominent lipid antigen in both the peripheral and central nervous systems. Anti‐sulfatide antibodies are detected in axonal and demyelinating neuropathies and are generally regarded as concomitant antibodies. However, their pathogenic role and precise diagnostic relevance remain unclear. Methods: This double‐center retrospective observational study tested anti‐sulfatide and antiganglioside antibodies using immunoblot assays in serum and/or cerebrospinal fluid (CSF) from patients suspected of having peripheral neuropathy. Clinical symptoms, laboratory findings, and electrophysiological results were reviewed for patients with anti‐sulfatide antibodies. Results: The most common symptoms in adult‐onset patients with anti‐sulfatide antibody included motor weakness (81.25%) and superficial sensory disturbances (68.75%). Patients with anti‐sulfatide antibodies in the CSF exhibited a higher frequency of CSF albuminocytological dissociation. Positive blood rheumatic antibodies and factors were more prevalent in seropositive patients. Electrophysiological findings revealed both axonal and demyelinating changes in these patients. Intravenous corticosteroids, immunoglobulins, and plasmapheresis proved effective treatments. Conclusions: The clinical manifestations of patients with anti‐sulfatide antibodies are highly heterogeneous. Anti‐sulfatide antibodies cause axonal and demyelinating damage in autoimmune peripheral neuropathy, presenting distinct clinical and electrophysiological features.Keywords
Funding Information
- Taishan Scholar Project of Shandong Province (202211318)
- Natural Science Foundation of Shandong Province (ZR2024MH051)
- Natural Science Foundation of Shandong Province (ZR2021QH161)
- National Natural Science Foundation of China (82171245)
- National Natural Science Foundation of China (82101487)
This publication has 29 references indexed in Scilit:
- Anti-sulfatide antibodies in neurological disorders: should we test?Journal of Neurology, 2024
- Clinical and diagnostic features of anti‐neurofascin‐155 antibody‐positive neuropathy in Han ChineseAnnals of Clinical and Translational Neurology, 2022
- Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian databaseNeurological Sciences, 2022
- Anti‐ganglioside autoantibodies in type 1 diabetesMuscle & Nerve, 2009
- Myelin‐associated glycoprotein and its axonal receptorsJournal of Neuroscience Research, 2009
- Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?Journal of Neurology, 2009
- The Role and Metabolism of Sulfatide in the Nervous SystemMolecular Neurobiology, 2008
- Involvement of sulfatide in beta cells and type 1 and type 2 diabetesDiabetologia, 2005
- A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytesJournal of Neuroimmunology, 1995
- Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitusThe Lancet, 1993